Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia

Trial Profile

Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vatiquinone (Primary)
  • Indications Friedreich's ataxia
  • Focus Therapeutic Use
  • Sponsors BioElectronics Corporation; Edison Pharmaceuticals
  • Most Recent Events

    • 28 Apr 2017 Primary endpoint of Visual Function has not been met, according to results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
    • 18 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top